FXYD3: A promising biomarker for urothelial carcinoma

Biomarker Insights

Volumn 6, Issue , 2011, Pages 17-26

  Zhang, Zhongfa ^a,f   Pang, See Tong ^b   Kasper, Katherine A ^c   Luan, Chunyan ^c   Wondergem, Bill ^a   Lin, Fan ^d   Chuang, Cheng Keng ^b   The, Bin Tean ^a,e   Yang, Ximing J ^c  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f WISTAR INSTITUTE   (United States)

Author keywords

FXYD; FXYD3; Kidney; Marker; Microarray; Urothelial carcinoma

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN FXYD3; PROTEIN P63; PROTEIN S 100; PROTEIN S 100P; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; ONCOCYTOMA; PAPILLOMA; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSITIONAL CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 79952925205     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S6487     Document Type: Article

References (26)

1. Higgins JP, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31(5):673-80
2. Phatak S, Kolwadkar P. Renal and ureteral transitional cell carcinoma: A case report. 2006;16(4):907-9
3. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 2003;47(2):155-69
4. Catto JW, et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol. 2007;177(5):1715-20
5. Zhang Z, et al. Comparative gene expression profiling analysis of urothelial carcinoma of renal pelvis and bladder. BMC Medical Genomics. 2010; Accepted.
6. Langner C, et al. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem. 2003;51(8):1097-9
7. Skinnider BF, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29(6):747-54
8. Phe V, Cussenot O, Roupret M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 2009;104(7): 896-901
9. Han AC, Duszak R Jr. Coexpression of cytokeratins 7 and 20 confirms urothelial carcinoma presenting as an intrarenal tumor. Cancer. 1999;86(11):2327-30
10. Yang XJ, et al. Classification of renal neoplasms based on molecular signatures. J Urol. 2006;175(6):2302-6
11. Dai M, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005;33(20):el75.
12. Sauter G, et al. Noninvasive urothelial neoplasias: WHO classification of noninvasive papillary urothelial tumors. In World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. In: Eble JN, Epstein JI, Sesterhenn I, editors. Lyon, IARCC Press, 2004:110.
13. Yang XJ, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65(13):5628-37
14. Tretiakova MS, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28(1):69-76
15. Chuang ST, et al. Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol. 2008;179(2):445-9
16. Ring BZ, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol. 2009;22(8):1032-43
17. Crambert G, et al. FXYD3 (Mat-8), a new regulator of Na,K-ATPase. Mol Biol Cell. 2005;16(5):2363-71
18. Geering K. FXYD proteins: new regulators of Na-K-ATPase. Am J Physiol Renal Physiol. 2006;290(2):F241-50
19. Sweadner KJ, Rael E. The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics. 2000;68:41.
20. Takahashi M, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22(43):6810-8
21. Morrison BW, et al. Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in Xenopus oocytes. J Biol Chem. 1995;270:2176.
22. Schiemann SSM, Brunner N, Weidle UH. Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. Clin Exp Metastasis. 1988;16:129-39
23. Vaarala MH, et al. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest. 2000;80(8):1259-68
24. Grzmil M, et al. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int J Oncol. 2004;24(1):97-105
25. Kayed H, et al. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer. 2006;118(1):43-54
26. Izquierdo L, et al. Molecular characterization of upper urinary tract tumours. BJU Int. 2010;106(6):868-72